NEOGEN CORP

NEOG · XNAS

CIK 711377fmd_09T7YGR19CVSWMNKANR735X9GDManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Jun 01, 2009 to Aug 31, 2026, 66 periods

Income Statement · Annual · Millions · USD
Line item	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Total revenues	358	398	414	418	468	527	822	924	895	870
Cost of revenue	189	212	222	222	253	284	416	460	473	462
Gross profit	169	186	192	196	215	243	406	464	421	409
Research and development	10	11	13	15	16	17	26	23	21	18
Selling, general and administrative	94	105	111	114	125	167	342	383	402	412
Total operating expenses	104	116	124	129	141	184	368	405	1,482	430
Operating income	65	70	68	68	74	59	38	59	(1,061)	(22)
Interest expense	–	–	–	–	–	–	27	42	38	24
Interest and investment income	1	–	–	–	–	–	–	–	–	–
Other non-operating income (expense)	2	3	5	5	1	2	(60)	(73)	(72)	13
Income before taxes	67	73	73	72	75	60	(22)	(14)	(1,133)	(9)
Income tax expense	23	10	13	13	14	12	1	(5)	(41)	(1)
Net income from continuing operations	44	63	60	59	61	48	(23)	(9)	(1,092)	(8)
Net income	44	63	60	59	61	48	(23)	(9)	(1,092)	(8)